RUA Life Sciences (LSE:RUA) Debt-to-EBITDA : (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RUA RUA Life Sciences PLC LSE:RUA
34 GF Score
Price £0.27
GF Value £0.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is RUA Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RUA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was £0.17 Mil. RUA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was £0.49 Mil. RUA Life Sciences's annualized EBITDA for the quarter that ended in Mar. 2026 was £0.13 Mil. RUA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was 4.93.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RUA Life Sciences's Debt-to-EBITDA or its related term are showing as below:

LSE:RUA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.32   Med: -0.24   Max: 93
Current: 93

During the past 13 years, the highest Debt-to-EBITDA Ratio of RUA Life Sciences was 93.00. The lowest was -0.32. And the median was -0.24.

LSE:RUA's Debt-to-EBITDA is ranked worse than
100% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs LSE:RUA: 93.00

RUA Life Sciences  (LSE:RUA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

RUA Life Sciences Debt-to-EBITDA Related Terms

RUA Life Sciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for RUA Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RUA Life Sciences Debt-to-EBITDA Chart

RUA Life Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Sep25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RUA Life Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Mar25 Sep25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LSE:RUA vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, RUA Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RUA Life Sciences Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Debt-to-EBITDA falls into.


LSE:RUA
34GF Score
RUA Life Sciences PLC LSE:RUA
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RUA Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RUA Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Sep. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.234 + 0.56) / 0.28600143
=2.78

RUA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.166 + 0.485) / 0.132
=4.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.

Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?

Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued. The current stock price of £0.27 is trading 80% above its estimated GF Value™ of £0.15. GuruFocus considers RUA Life Sciences to be Significantly Overvalued.

Key valuation signals for LSE:RUA:

  • Debt-to-EBITDA:
  • GF Value™: £0.15 vs. price of £0.27 (80% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RUA Life Sciences Business Description

Other Exchanges AOHA:Germany
Address 2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
34GF Score

Get the complete analysis for LSE:RUA

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.27
Price
£0.15
GF Value